The practical management of refractory schizophrenia – the Maudsley Treatment REview and Assessment Team service approach

@article{Beck2014ThePM,
  title={The practical management of refractory schizophrenia – the Maudsley Treatment REview and Assessment Team service approach},
  author={Katherine Beck and Robert A. McCutcheon and Martha Aladjem Bloomfield and Fiona Gaughran and Tiago Reis Marques and James MacCabe and Sudhakar Selvaraj and David Taylor and Oliver D Howes},
  journal={Acta Psychiatrica Scandinavica},
  year={2014},
  volume={130}
}
To describe a practical approach to the community management of treatment‐resistant schizophrenia (TRS). 

Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia

Investigation of the prevalence of subtherapeutic antipsychotic plasma levels in patients identified as treatment‐resistant by their treating clinician found them to be high.

Possible pharmacogenetic factors in clozapine treatment failure: a case report

Therapeutic drug monitoring together with early pharmacogenetic testing may offer a path for some patients with refractory psychotic symptoms unresponsive to clozapine treatment.

Prevalence of treatment-resistant psychoses in the community: A naturalistic study

The findings suggest that TRS is common in the community mental-health team, and a large proportion of these patients have not received clozapine, and indicate that identifying and treating treatment resistance should be a focus of community services for schizophrenia.

Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology

These updated guidelines from the British Association for Psychopharmacology replace the original version published in 2011 and address the scope and targets of pharmacological treatment for schizophrenia, including first-episode, relapse prevention, and illness that has proved refractory to standard treatment.

Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses

For the majority of the TR group, antipsychotic TR is present from illness onset, necessitating increased consideration for the earlier use of clozapine.

A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia

An overview of strategies to support early initiation of clozapine in patients with TRS is provided based on the latest evidence and the clinical experience, and the key elements in a practical, evidence-based checklist for identifying and managing patients are summarized.

University of Birmingham Prevalence of treatment resistance and clozapine use in early intervention services

Treatment resistance causes significant burden in psychosis. Clozapine is the only evidence-based pharmacologic intervention available for people with treatment-resistant schizophrenia; current

References

SHOWING 1-10 OF 64 REFERENCES

Schizophrenia: core interventions in the treatment and management

  • Nice
  • Medicine, Psychology
  • 2005
NICE and the National Collaborating Centre for Mental Health have published a guideline for the NHS in England and Wales on the treatment and management of schizophrenia.

Practitioner attitudes to clozapine initiation

This survey aimed to clarify barriers to prescribing and elucidate factors that may improve patient access to clozapine, the most effective antipsychotic for treatment‐resistant schizophrenia.

Lishman's Organic Psychiatry: A Textbook of Neuropsychiatry

Lishman's Organic Psychiatry: A Textbook of Neuropsychiatry - Libros de Medicina - Neuropsiquiatria - 78,00

Lishman's Organic Psychiatry

LISHMANS ORGANIC PSYCHIATRY , LISHMANS ORGANIC PSYCHIATRY , کتابخانه مرکزی دانشگاه علوم پزشکی ایران

The social and economic burden of treatment-resistant schizophrenia: a systematic literature review

The societal and economic burden of treatment-resistant schizophrenia (TRS) remains common and costly, despite availability of many treatment options, and contributes to a significant loss in patient quality of life.

Optimizing clozapine treatment

It is necessary to select patients suitable for high-efficacious use for clozapine treatment based on prior history and once they provide informed consent for the use of this drug, the results show.

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials.

It is confirmed that treatment-resistant schizophrenic patients have more favorable outcomes when treated with clozapine rather than a typical antipsychotic, as reflected by Brief Psychiatric Rating Scale total score, categorical response rate, Scale for the Assessment of Negative Symptoms score, Simpson-Angus Rating Scale score, and compliance rate.

Clozapine: guidelines for clinical management.

Clozapine is an experimental neuroleptic with atypical properties that has shown superior antipsychotic efficacy in treatment-refractory schizophrenics and a more favorable extrapyramidal side effect profile in comparison with standard neuroleptics.

Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology

  • T. Barnes
  • Medicine, Psychology
    Journal of psychopharmacology
  • 2011
These guidelines from the British Association for Psychopharmacology address the scope and targets of pharmacological treatment for schizophrenia, and cover the pharmacological management and treatment of schizophrenia across the various stages of the illness.

Cognitive–behavioural therapy for refractory psychotic symptoms of schizophrenia resistant to atypical antipsychotic medication

Cognitive–behavioural therapy showed modest short-term benefits over supportive counselling for treatment-refractory positive symptoms of schizophrenia, but these findings were not maintained at follow-up.
...